GW Vitek Co Ltd
036180
Company Profile
Business description
GW Vitek Co Ltd is engaged in teh business divisions of Bio Business Division, which focuses on the development and production of research antibodies, the manufacturing and sales of ELISA kits, and the development of antibodies and ELISA kits for biopharmaceutical QC, the manufacturing and sales of transformer deterioration diagnostic kits, the manufacturing and sales of research reagents, and genome analysis services. The Scientific Equipment Business Division supplies biotechnology-related scientific instruments and consumables.
Contact
244 Beotkkot-ro
11th floor
Geumcheon-gu
Seoul
KORT: +82 221403300
Sector
Technology
Stock type
Sensitive
Industry
Scientific & Technical Instruments
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,238.17 | 23.99 | -0.29% |
| DAX 40 | 24,491.06 | 111.98 | -0.46% |
| Dow JONES (US) | 49,053.22 | 448.08 | -0.91% |
| FTSE 100 | 10,309.22 | 93.12 | -0.90% |
| HKSE | 26,580.48 | 304.76 | -1.13% |
| NASDAQ | 22,540.59 | 363.99 | -1.59% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,821.72 | 61.00 | -0.89% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |